A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
1. Age 18-60
2. Subject has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex-designated investigational clinical study assay.
1. History of organ / bone marrow transplantation
2. Diagnosis of Diabetes Mellitus
3. History of human immunodeficiency virus (HIV), hepatitis B (HBV) infection, or hepatitis C (HCV) infection.
If you aren't sure if you qualify, please call us and we will help determine your eligibility.
This study will last approximately 2 years. Patients will have visits approximateley every 4 weeks, blood drawn, ECGs taken, and vitals taken. Home health visits available.